AI-Based Respiratory Monitoring-Guided Evaluation of Rottlerin Therapy for PRRS in Grower-Finisher Pig Farms

Porcine reproductive and respiratory syndrome virus (PRRSV) remains a major cause of economic loss in the swine industry, and highly pathogenic variants such as NADC34-like PRRSV highlight the need for antiviral strategies that complement vaccination. In this field study, we evaluated the efficacy of AlimenWOW, a rottlerin-lipid formulation, in grower-finisher pigs under commercial conditions using AI-based respiratory monitoring. A total of 2000 pigs were assigned to four groups: AlimenWOW G1 (PRRSV-stable source farm), AlimenWOW G2 (PRRSV-unstable source farm), Control 1 (antibiotic), and Control 2 (antipyretic). Respiratory Health Status (ReHS) and a derived Clinical Cough Index (CCI = 100 - ReHS) were continuously recorded with SoundTalks^®, and oral fluid PRRSV load, serology, clinical outcomes, and productivity were assessed over 4 weeks. AlimenWOW G2 showed a marked improvement in ReHS from severely compromised baseline values to levels comparable with healthy status, while both control groups remained low; CCI was significantly lower in AlimenWOW G2 than in controls from day 14 onward (p ≤ 0.0001). AlimenWOW treatment was associated with reduced PRRSV titers in oral fluid, lower mortality and wasting rates, and improved feed conversion with lower feed costs compared with controls. These findings indicate that AlimenWOW, integrated with AI-based acoustic monitoring, can improve respiratory health and mitigate PRRSV-associated clinical and economic losses, supporting its use as a complementary tool in PRRSV control programs.